Transcutaneous Electrical Acustimulation in the Treatment of Mild to Moderate Ulcerative Colitis
NCT ID: NCT06231264
Last Updated: 2025-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
96 participants
INTERVENTIONAL
2024-01-19
2026-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Safety and Efficacy of TET Enema in the Treatment of UC
NCT03917095
Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis
NCT01221428
Clinical Response and Safety Following FMT for UC
NCT04294615
Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Active Ulcerative Colitis
NCT02442037
Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis
NCT04231110
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
treatment group
Subjects will be trained to use the devices at the treatment sites and receive treatment twice a day for 8 weeks.
transcutaneous electrical acustimulation at treatment sites
A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the treatment site. The precise stimulating sites are not described upon registration to reduce unblinding risk.
shame group
Subjects will be trained to use the devices at the sham sites and receive sham treatment twice a day for 8 weeks.
transcutaneous electrical acustimulation at sham sites
A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the sham treatment sites. The precise stimulating sites are not described upon registration to reduce unblinding risk.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
transcutaneous electrical acustimulation at treatment sites
A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the treatment site. The precise stimulating sites are not described upon registration to reduce unblinding risk.
transcutaneous electrical acustimulation at sham sites
A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the sham treatment sites. The precise stimulating sites are not described upon registration to reduce unblinding risk.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Ulcerative colitis diagnosed for at least 3 mouths.
3. Mayo score 4-10, Mayo endoscopic score 2-3 points
4. Resistant to at least one type of medical treatments
Exclusion Criteria
2. Acute severe ulcerative colitis
3. Previous surgical treatment or severe colitis at imminent risk of surgery infective colitis
4. Other systemic diseases
5. Pregnancy and lactation
6. Allergic to the electrode patch
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xijing Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kaichun Wu
Role: PRINCIPAL_INVESTIGATOR
Xijing Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Honghui hospital
Xi'an, Shaanxi, China
Second Affiliated Hospital of Xi 'an Jiaotong University
Xi'an, Shaanxi, China
Tangdu Hospital
Xi'an, Shaanxi, China
Xijing Hospital
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Shuang Han
Role: primary
Sumei Sha
Role: primary
Ning Wang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY20232371
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.